LISINOPRIL VIATRIS 20 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

lisinopril viatris 20 mg, comprimé sécable

viatris sante - lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté - comprimé - 20 mg - pour un comprimé > lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté - inhibiteurs de l'enzyme de conversion - classe pharmacothérapeutique : inhibiteurs de l'enzyme de conversion - code atc : c09aa03.le lisinopril appartient à la classe des inhibiteurs de l'enzyme de conversion de l'angiotensine (iec). il agit en dilatant les vaisseaux sanguins, ce qui contribue à faire baisser la pression artérielle et facilite le travail du cœur pour envoyer le sang dans toutes les parties de l’organisme.lisinopril viatris est indiqué en cas de : pression artérielle trop élevée (hypertension artérielle) ; insuffisance cardiaque ; crise cardiaque (infarctus du myocarde) récente ; problèmes rénaux en cas de diabète de type ii et d'hypertension artérielle.

LISINOPRIL tablet
LISINOPRIL tablet USA - engelsk - NLM (National Library of Medicine)

lisinopril tablet lisinopril tablet

stat rx usa llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 20 mg - lisinopril tablet is indicated for the treatment of hypertension. it may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. lisinopril tablet is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. lisinopril tablet is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. in using lisinopril tablet, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril tablet does not have a similar risk (see warnings). in considering the use of lisinopril tablet, it should

LISINOPRIL GENERIC HEALTH lisinopril 20mg tablets blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

lisinopril generic health lisinopril 20mg tablets blister pack

generic health pty ltd - lisinopril dihydrate, quantity: 21.78 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: maize starch; pregelatinised maize starch; iron oxide red; colloidal anhydrous silica; mannitol; magnesium stearate; calcium hydrogen phosphate dihydrate - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

LISINOPRIL GENERIC HEALTH lisinopril 10mg tablets blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

lisinopril generic health lisinopril 10mg tablets blister pack

generic health pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide red; colloidal anhydrous silica; mannitol; maize starch; calcium hydrogen phosphate dihydrate; pregelatinised maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

LISINOPRIL GENERIC HEALTH lisinopril 5mg tablets blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

lisinopril generic health lisinopril 5mg tablets blister pack

generic health pty ltd - lisinopril dihydrate, quantity: 5.44 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: iron oxide red; calcium hydrogen phosphate dihydrate; mannitol; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

PIP-LISINOPRIL lisinopril (as dihydrate) 20mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pip-lisinopril lisinopril (as dihydrate) 20mg tablet blister pack

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

PIP-LISINOPRIL lisinopril (as dihydrate) 10mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pip-lisinopril lisinopril (as dihydrate) 10mg tablet blister pack

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

PIP-LISINOPRIL lisinopril (as dihydrate) 5mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pip-lisinopril lisinopril (as dihydrate) 5mg tablet blister pack

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

PIP-LISINOPRIL lisinopril (as dihydrate) 2.5mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pip-lisinopril lisinopril (as dihydrate) 2.5mg tablet blister pack

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

LISINOPRIL/HYDROCHLOROTHIAZIDE BIOGARAN 20 mg/12,5 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

lisinopril/hydrochlorothiazide biogaran 20 mg/12,5 mg, comprimé sécable

biogaran - lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > lisinopril anhydre 20 mg sous forme de : lisinopril dihydraté > hydrochlorothiazide 12,5 mg - inhibiteur de l'enzyme de conversion (iec) et diuretiques - classe pharmacothérapeutique : inhibiteur de l’enzyme de conversion (iec) et diuretiques - code atc : c09ba03.ce médicament est indiqué dans le traitement de : l'hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l'enzyme de conversion).